Clinical Trial Update: Golidocitinib Combined With Selinexor for CAEBVD [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/phase 3 clinical trial evaluating golidocitinib in combination with selinexor for chronic active Epstein-Barr virus disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Active Epstein-barr Virus Infection
• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• Golidocitinib (golidocitinib)
• Selinexor (selinexor)

Snippet

Sponsor: Beijing Friendship Hospital | Conditions: Lymphohistiocytosis, EBV | Phase 2, Phase 3 | Status: RECRUITING